Related Experiment Video
Updated: Aug 9, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung
Richard F Riedel1, Phillip G Febbo
1Duke University Medical Center, Division of Hematology, Department of Medicine, Durham, NC 27710, USA. richard.riedel@duke.edu
Abstract:
Despite advances in chemotherapeutics, overall survival for advanced lung cancer patients remains poor. Consequently, efforts have focused on the use of targeted therapies to improve response rates and survival. The epidermal growth factor receptor (EGFR) is overexpressed in a variety of cancers, including lung, and may play a critical role in the pathogenesis of disease. Small molecule tyrosine kinase inhibitors, such as gefitinib (Iressa(R)), have response rates of between 10 and 27% in Phase II trials, and anecdotal reports of dramatic and sustained responses. Two recent studies published simultaneously, identified mutations in the ATP-binding cleft of the EGFR that are associated with clinical response to gefitinib. This finding has extraordinary implications and serves as a critical step toward individualized, patient-specific treatment plans based on the molecular constitution of the tumor of each individual.
Insights
Targeted therapies like gefitinib show promise for advanced lung cancer. Mutations in the epidermal growth factor receptor (EGFR) are linked to patient response, paving the way for personalized cancer treatments.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacogenomics
Background:
- Advanced lung cancer survival rates remain low despite chemotherapy advancements.
- Targeted therapies are being explored to improve treatment efficacy and patient outcomes.
- Epidermal growth factor receptor (EGFR) overexpression is implicated in various cancers, including lung cancer.
Purpose of the Study:
- To investigate the role of epidermal growth factor receptor (EGFR) in lung cancer pathogenesis.
- To evaluate the efficacy of targeted therapies, specifically gefitinib, in advanced lung cancer patients.
- To identify molecular markers associated with gefitinib response.
Main Methods:
- Phase II clinical trials were conducted to assess gefitinib response rates.
- Simultaneous studies analyzed mutations within the ATP-binding cleft of EGFR.
- Correlation between EGFR mutations and clinical response to gefitinib was examined.
Main Results:
- Gefitinib demonstrated response rates of 10-27% in Phase II trials.
- Anecdotal reports indicated dramatic and sustained responses to gefitinib.
- Specific mutations in the EGFR ATP-binding cleft were identified and associated with gefitinib response.
Conclusions:
- EGFR mutations are predictive biomarkers for gefitinib treatment in lung cancer.
- This discovery represents a significant advancement towards individualized cancer therapy.
- Molecular profiling of tumors will enable tailored treatment strategies for lung cancer patients.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Related Concept Videos
02:38Mitogens and the Cell Cycle
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase